Fig. 2: QPOP to guide treatment response in an SFT patient. | npj Precision Oncology

Fig. 2: QPOP to guide treatment response in an SFT patient.

From: Functional combinatorial precision medicine for predicting and optimizing soft tissue sarcoma treatments

Fig. 2

a Treatment timeline for the patient. The green circle denotes the time point at which QPOP analysis was performed. b (i) Forest plot depicting QPOP-derived normalized cell viability (NCV) scores (mean ± SD) of top-ranked single agents in comparison to other standard therapies. (ii) Single-drug dose-response curve of pazopanib in hSC06. (iii) Computed tomography (CT) imaging of the dominant liver metastasis progressing on liposomal doxorubicin and (iv) before and after pazopanib treatment. c (i) Forest plot depicting QPOP-derived normalized cell viability (NCV) scores (mean ± SD) of top-ranked single agents in comparison to other standard therapies. (ii) Single-drug dose-response curve of pazopanib in hSC31. (ii) Magnetic resonance imaging (MRI) of the locally recurrent primary brain lesion progressing on pazopanib and (iv) before and after treatment with eribulin.

Back to article page